SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS

  Back
SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than January 23, 2025. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/61f8a35bebc5632acfd450537014e21e.pdf
Vlado
Perkovic
9
Dana Rizk drizk@uabmc.edu University of Alabama at Birmingham Birmingham United States
Dmitrij Kollins dmitrij.kollins@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel Switzerland
Olympia Papachristofi olympia.papachristofi@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel Switzerland
Thomas Hach thomas.hach@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel Switzerland
Severina Jacinto-Sanders severina.jacinto-sanders@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic GDD Basel Switzerland
Tobias Merkel tobias.merkel@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic Basel Switzerland
Robert Schmouder robert.schmouder@novartis.com Novartis Pharmaceuticals Corporation Cardio-Renal-Metabolic East Hanover, NJ United States
Kenneth Kulmatycki kenneth.kulmatycki@novartis.com Novartis Institutes for Biomedical Research Cardio-Renal-Metabolic Cambridge, MA United States
Ronny Renfurm ronny.renfurm@novartis.com Novartis Pharma AG Cardio-Renal-Metabolic Basel Switzerland
Vlado Perkovic vlado.perkovic@unsw.edu.au University of New South Wales Renal and Metabolic Division Sydney Australia